Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • ImmunoCellular Therapeutics Ltd. (IMUC) To Be Added To Russell Indexes 0 comments
    Jun 18, 2012 1:24 PM | about stocks: IMUC

    ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies to diagnose and treat brain and other cancers. The company has begun a Phase II trial of its lead product candidate, ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.

    The company announced today that it is scheduled to join the US broad market Russell 3000, Russell Global, and Russell Microcap Indexes when Russell Investments reconstitutes its comprehensive set of US and global equity indexes on June 25, 2012. This is according to a list of additions posted on June 8 on the Russell website at www.russell.com/indexes. The Russell 3000 index serves as the US component for the Russell Global index.

    The Russell Indexes are widely used by investment managers and institutional investors for index funds and as industry-wide benchmarks for both passive and active investment strategies. According to Russell Investments, an industry-leading $3.9 trillion in assets are currently benchmarked to the various Russell indexes.

    ImmunoCellular considers the imminent move of its stock into the Russell indexes to be an important step in the company's efforts to increase liquidity in its stock and broaden its investor base among major institutional investors. It believes the timing of its inclusion into the indexes is ideal as it should increase investor awareness ahead of the clinical results from its Phase II trial of ICT-107.

    To learn more about ImmunoCellular Therapeutics and its ICT-107 product candidate, please visit the company's website at www.imuc.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: IMUC
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.